McMaster EMBRACE study receives $4.9M from Pfizer

The McMaster University-led EMBRACE study—focused on improving care for Canadians who are living with a blood cancer called multiple myeloma—is receiving $4.9M from Pfizer. With this funding, the study will evaluate whether adult patients with relapsed or refractory multiple myeloma can be remotely monitored so that they can safely receive treatment and care at home. The researchers will also examine whether increasing the treatment dosing intervals may help reduce the risk of infection. EMBRACE will be launched at five sites across Canada this July.